Results 271 to 280 of about 5,057,415 (322)

ISOLATION OF THE RICKETTSIAL INHIBITOR FROM AUTOCLAVED DIPHOSPHOPYRIDINE NUCLEOTIDE

, 1954
Sheldon Rosenberg, Marianna R. Bovarnick
openalex   +1 more source

Modeling and Interpretability Study of the Structure-Activity Relationship for Multigeneration EGFR Inhibitors. [PDF]

ACS Omega
Sun Z, Huo D, Guo J, Yan A.
europepmc   +1 more source

Ubiquitination of transcription factors in cancer: unveiling therapeutic potential

Molecular Oncology, EarlyView.
In cancer, dysregulated ubiquitination of transcription factors contributes to the uncontrolled growth and survival characteristics of tumors. Tumor suppressors are degraded by aberrant ubiquitination, or oncogenic transcription factors gain stability through ubiquitination, thereby promoting tumorigenesis.
Dongha Kim, Hye Jin Nam, Sung Hee Baek
wiley   +1 more source

Corrosion inhibition and <i>in silico</i> toxicity assessment of imidazo[1,2-<i>a</i>]pyrimidine-Schiff base derivatives as effective and environmentally friendly corrosion inhibitors for mild steel. [PDF]

RSC Adv
Azzouzi M, Daoudi W, Dagdag O, Berisha A, Kim H, Oussaid A, El Aatiaoui A, Oussaid A.   +7 more
europepmc   +1 more source

Targeted protein degradation in oncology: novel therapeutic opportunity for solid tumours?

Molecular Oncology, EarlyView.
Current anticancer therapies are limited by the occurrence of resistance and undruggability of most proteins. Targeted protein degraders are novel, promising agents that trigger the selective degradation of previously undruggable proteins through the recruitment of the ubiquitin–proteasome machinery. Their mechanism of action raises exciting challenges,
Noé Herbel, Sophie Postel‐Vinay
wiley   +1 more source

Growth-promoting and Growth-inhibiting Substances in the Petiole

, 1940
Yasuyuki Okabe
openalex   +2 more sources

Effectiveness of First-Line Treatment with Anaplastic Lymphoma Kinase and ROS1 Protoncogene Inhibitors in Non-Small Cell Lung Cancer Patients-Real-World Evidence of Two Polish Cancer Centers. [PDF]

Cancers (Basel)
Gil M, Winiarczyk K, Krawczyk P, Wojas-Krawczyk K, Łomża-Łaba A, Obara A, Gajek Ł, Reszka K, Tysarowski A, Buczkowski J, Chmielewska I, Jankowski T, Szuba-Gil M, Strzemski M, Kowalski DM, Milanowski J, Krzakowski M.   +16 more
europepmc   +1 more source

Aberrant expression of nuclear prothymosin α contributes to epithelial‐mesenchymal transition in lung cancer

Molecular Oncology, EarlyView.
Nuclear prothymosin α inhibits epithelial‐mesenchymal transition (EMT) in lung cancer by increasing Smad7 acetylation and competing with Smad2 for binding to SNAI1, TWIST1, and ZEB1 promoters. In early‐stage cancer, ProT suppresses TGF‐β‐induced EMT, while its loss in the nucleus in late‐stage cancer leads to enhanced EMT and poor prognosis.
Liyun Chen, Chung‐Teng Wang, Jia‐Ming Chang, Ai‐Li Shiau, Gia‐Shing Shieh, Yau‐Lin Tseng, Yi‐Ting Yen, Tang‐Hsiu Huang, Li‐Hsin Cheng, Yu‐Chih Wu, Chao‐Liang Wu, Bing‐Hua Su, Pensee Wu   +12 more
wiley   +1 more source

Further studies on the inhibiting substance that prevents the self-fertilization of the Japanese radish. 1

, 1959
Tamio Tatebe
openalex   +2 more sources

Development of CD73 Inhibitors in Tumor Immunotherapy and Opportunities in Imaging and Combination Therapy. [PDF]

J Med Chem
Bi C, Patel JS, Liang SH.
europepmc   +1 more source